NASDAQ:MBRX Moleculin Biotech (MBRX) Stock Price, News & Analysis $0.49 -0.02 (-3.37%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.48 -0.01 (-1.19%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Moleculin Biotech Stock (NASDAQ:MBRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Moleculin Biotech alerts:Sign Up Key Stats Today's Range$0.47▼$0.5150-Day Range$0.39▼$2.1952-Week Range$0.16▼$15.75Volume421,551 shsAverage Volume1.25 million shsMarket Capitalization$9.48 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Moleculin Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancers that are difficult to treat or have limited therapeutic options. The company’s research programs target cancer-cell survival mechanisms, drug resistance and tumor metabolism. Moleculin’s lead product candidate is annamycin, a liposomal formulation of doxorubicin designed to retain anticancer activity while reducing the risk of cardiotoxicity associated with some conventional anthracyclines. The company has studied annamycin in investigational programs for acute myeloid leukemia and soft-tissue sarcoma. Annamycin remains an investigational therapy and is not approved for commercial use. The company is also developing additional preclinical and clinical-stage candidates, including WP1066, which targets STAT3 and related signaling pathways, and WP1122, which is designed to interfere with glucose metabolism in cancer cells. Moleculin’s programs are being evaluated through research and clinical development activities in the United States and other regions. The company is headquartered in Houston, Texas, and is led by Walter Klemp, who serves as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Moleculin Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreMBRX MarketRank™: Moleculin Biotech scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMoleculin Biotech has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMoleculin Biotech has a consensus price target of $3.00, representing about 516.3% upside from its current price of $0.49.Amount of Analyst CoverageMoleculin Biotech has only been the subject of 2 research reports in the past 90 days.Read more about Moleculin Biotech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($2.37) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moleculin Biotech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moleculin Biotech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Moleculin Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.80% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 0.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently increased by 61.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.51 News SentimentMoleculin Biotech has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Moleculin Biotech this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MBRX on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat Follows2 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders18.04% of the stock of Moleculin Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.52% of the stock of Moleculin Biotech is held by institutions.Read more about Moleculin Biotech's insider trading history. Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MBRX Stock News HeadlinesAnalysts Are Bullish on These NA Stocks: Moleculin Biotech (MBRX), Alphabet Class A (GOOGL)October 2 at 3:08 AM | theglobeandmail.comMoleculin Completes Part A Enrollment In Phase 2/3 MIRACLE Trial For Relapsed AMLSeptember 29, 2026 | rttnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data ReadoutSeptember 29, 2026 | globenewswire.comMoleculin Reports Cardiac Safety Findings For Annamycin In Pooled AnalysisSeptember 28, 2026 | rttnews.comMoleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular MedicineSeptember 28, 2026 | finance.yahoo.comMoleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular MedicineSeptember 28, 2026 | globenewswire.comAnnamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACRSeptember 25, 2026 | globenewswire.comSee More Headlines MBRX Stock Analysis - Frequently Asked Questions How have MBRX shares performed this year? Moleculin Biotech's stock was trading at $3.31 at the beginning of 2026. Since then, MBRX stock has decreased by 85.3% and is now trading at $0.4868. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) announced its quarterly earnings data on Thursday, August, 13th. The company reported ($1.40) EPS for the quarter, beating analysts' consensus estimates of ($1.55) by $0.15. When did Moleculin Biotech's stock split? Moleculin Biotech shares reverse split before market open on Monday, December 1st 2025.The 1-25 reverse split was announced on Wednesday, November 26th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Moleculin Biotech IPO? Moleculin Biotech (MBRX) raised $8 million in an IPO on Thursday, June 2nd 2016. The company issued 1,540,026 shares at $5.00-$6.00 per share. How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Moleculin Biotech investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Company Calendar Last Earnings8/13/2026Today10/03/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, MBRX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MBRX CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees17Year Founded2006Price Target and Rating Average Price Target for Moleculin Biotech$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+516.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($7.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-143.51% Return on Assets-24.53% Debt Debt-to-Equity RatioN/A Current Ratio0.94 Quick Ratio0.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.69 per share Price / Book0.10Miscellaneous Outstanding Shares19,480,000Free Float15,963,000Market Cap$9.48 million OptionableNot Optionable Beta2.00 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MBRX) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredTrump's crypto bank just got approvedLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
